JPRN-jRCT1011180032进行中(未招募)2 期
eoadjuvant nab-paclitaxel plus gemcitabine therapy for resectable pancreatic cancer; A phase II multicenter trial - HOPS-R02
Hirano Satoshi0 个研究点目标入组 50 人开始时间: 2019年3月27日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 79age old(—)
- 性别
- All
入选标准
- •1.Resectable pancreatic cancer (JPS7th)
- •2.Pathological or cytologically proven invasive ductal adenocarcinoma or adenosquamous carcinoma
- •3.No distant metastasis
- •4.Age over 20 or under 80
- •5.ECOG performance status 0-1
- •6.No history of chemo therapy within 3 years.
- •7.No history of pancreatic cancer therapy
- •8.No problems for oral intake
- •9.Neither peripheral sensory neuropathy nor peripheral motor neuropathy
- •10.In the case of obstructive jaundice, appropriate bileduct drainage is performed
- •11.No findings of gastrointestinal infiltration protruding into the lumen and or gastrointestinal bleeding
- •12.The latest inspection value within 2 weeks before registration satisfies all of the following.
- •1) White blood cell count more than 3,000 / mm 3
- •2) Hemoglobin more than 9.0 g / dL (no transfuse within 7 days before registration)
- •3) Platelet count more than 10 x 10 4 / mm 3
- •4) Albumin more than 3.0 g / dL
- •5) Total bilirubin less than 2.0 mg / dL (3.0 mg / dL or less in case of bileduct drainarge)
- •6) AST less than 100 U / L (150 IU / L or less in case of bileduct drainarge)
- •7) ALT less than 100 U / L (150 IU / L or less in case of bileduct drainarge)
- •8) Serum creatinine less than 1.2 mg / dL
- •9) Creatinine clearance 50 ml / min or more
- •13.Written informed consent
排除标准
- •1.GEM, nab-PTX or fluorinated pyrimidine anticancer drugs have been treated.
- •2.Severe diarrhea with uncontrolled bowel movement
- •3.Phenytoin, warfarin potassium, flucytosine are used.
- •4.History of sever allergic reaction with nab-paclitaxel, paclitaxel or albumin
- •5.Drug allergy to iodine contrast medium and impossible to perform contrast CT imaging. However, do not exclude the case of contrast-enhanced CT imaging with steroid prophylaxis.
- •6.Pulmonary fibrosis or interstitial pneumonia
- •7.Patients with medium or more pleural effusion or ascites
- •8.Active infection (Clinically stable HBV and chronic viral hepatitis by HCV are excluded).
- •9.Uncontrolled diabetes
- •10.Active double cancer (Synchronous double cancer and metachronous double cancer with disease-free period within 3 years). However, lesions such as carcinoma in situ that are cured by topical therapy are not included in active double cancers.
- •11.Active digestive ulcer
- •12.Serious complications (heart failure, renal failure, liver failure, intestinal palsy, etc).
- •13.Myocardial infarction within six months
- •14.Continuous systemic administration of steroids
- •15.Sever mental disorder
- •16.Women who are pregnant / lactating or pregnant or willing, or wish to baby.
- •17.A man who wishes to become a partner's pregnant.
- •18.Inappropriate physical condition as diagnosed by the attending physician
研究者
相似试验
已完成
不适用
eoadjuvant nab-paclitaxel plus gemcitabine therapy for resectable pancreatic cancer; A phase II multicenter trialResectable pancreatic cancerJPRN-UMIN000031822Hokkaido Pancreatic Cancer Study Group (HOPS)50
尚未招募
2 期
eoadjuvant Gemcitabine+nab-Paclitaxel for resectable and borderline resectable pancreatic cancer-feasibility study for the elderlyResectable and Borderline resectable pancreatic cancerJPRN-UMIN000048555Hyogo Prefectural Awaji Medical Center50
进行中(未招募)
1 期
Induction Treatment with nab-Paclitaxel/Gemcitabine for First-line Treatment of Metastatic Pancreatic Cancer Followed by Either Alternating Application of Gemcitabine Monotherapy and nab-Paclitaxel/Gemcitabine or Continuing Application of nab-Paclitaxel/Gemcitabine: A Randomized Phase II Studymetastatic pancreatic cancerMedDRA version: 21.1Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticSystem Organ Class: 100000004864EUCTR2014-004086-24-DEAIO-Studien-gGmbH325
已完成
不适用
Preoperative gemcitabine plus nab-paclitaxel, concurrent 3D conformal radiation therapy for borderline resectable pancreatic cancer: Phase I studypancreatic cancerJPRN-UMIN000012456Department of Gastroenterological Surgery, Osaka Medical Center for Cancer & Cardiovascular Diseases42
招募中
2 期
Preoperative gemcitabine plus nab-paclitaxel, concurrent 3D conformal radiation therapy for resectable pancreatic cancer: Phase II studypancreatic cancerJPRN-UMIN000018803Department of Gastroenterological Surgery, Osaka Medical Center for Cancer & Cardiovascular Diseases50
